Stereotaxis News

Stereotaxis to Report First Quarter 2024 Financial Results on May 13, 2024

ST. LOUIS, April 22, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial

GlobeNewswireApr 22 19:51

Canopy Growth, Exact Sciences, Stereotaxis Among Healthcare Movers

Seeking AlphaApr 2 22:00

Lake Street Keeps Their Buy Rating on Stereotaxis (STXS)

TipRanksMar 25 20:45

Stereotaxis Set for Breakout Growth: Buy Rating Affirmed Amidst Regulatory Advances and Robust Financials

TipRanksMar 18 18:35

Stereotaxis Is Maintained at Buy by Lake Street

Stereotaxis Is Maintained at Buy by Lake Street

Dow JonesMar 6 01:22

Stereotaxis Price Target Raised to $4.00/Share From $3.00 by Lake Street

Stereotaxis Price Target Raised to $4.00/Share From $3.00 by Lake Street

Dow JonesMar 6 01:22

Roth MKM Reiterates Buy on Stereotaxis, Maintains $5 Price Target

Roth MKM analyst Jason Wittes reiterates Stereotaxis with a Buy and maintains $5 price target.

Analyst UpgradesMar 5 23:23

Stereotaxis Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/05/2024 94.55% Roth MKM $5 → $5 Reiterates Buy → Buy 01/10/2024 94.55% Roth MKM → $5 Initiates Coverage

BenzingaMar 5 23:21

Stereotaxis Submits Magic Ablation Catheter for U.S., European Approval

MassDeviceMar 5 22:34

Earnings Call Summary | Stereotaxis(STXS.US) Q4 2023 Earnings Conference

The following is a summary of the Stereotaxis, Inc. (STXS) Q4 2023 Earnings Call Transcript:Financial Performance:Stereotaxis reported a decrease in Q4 2023 revenue to $4.6 million compared to $7.3 mi

Futu NewsMar 5 09:20 · Conference Call

Stereotaxis Anticipates Double Digit Revenue Growth For Full Year 2024; Sees Q1 Revenue Of ~$7M (Est $6.70M)

Stereotaxis Anticipates Double Digit Revenue Growth For Full Year 2024; Sees Q1 Revenue Of ~$7M (Est $6.70M)

BenzingaMar 5 06:22

12 Health Care Stocks Moving In Monday's After-Market Session

GainersVicarious Surgical (NYSE:RBOT) shares moved upwards by 24.9% to $0.45 during Monday's after-market session. The company's market cap stands at $78.6 million. As per the news, the Q4 earnings re

BenzingaMar 5 05:32

Stereotaxis Inc (STXS) Faces Revenue Pressure Amid Strategic Transformation

Yahoo FinanceMar 5 05:32

Stereotaxis Seeks Approval for New Cardiac Catheter

InvestingMar 5 05:18

Recap: Stereotaxis Q4 Earnings

Stereotaxis (AMEX:STXS) reported its Q4 earnings results on Monday, March 4, 2024 at 04:05 PM.Here's what investors need to know about the announcement.EarningsStereotaxis missed estimated earnings by

BenzingaMar 5 05:10

Stereotaxis 4Q Loss/Shr 7c >STXS

Stereotaxis 4Q Loss/Shr 7c >STXS

Dow JonesMar 5 05:09

Stereotaxis Q4 2023 GAAP EPS $(0.070), Inline, Sales $4.565M Miss $7.700M Estimate

Stereotaxis (AMEX:STXS) reported quarterly losses of $(0.070) per share which met the analyst consensus estimate. The company reported quarterly sales of $4.565 million which missed the analyst conse

BenzingaMar 5 05:07

Stereotaxis Announces Regulatory Submissions of the MAGiC Ablation Catheter in Europe and the United States

ST. LOUIS, March 04, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that regulatory submissions were

GlobeNewswireMar 5 05:06

Earnings Flash (STXS) STEREOTAXIS Reports Q4 Revenue $4.6M, Vs. Street Est of $7.7M

04:05 PM EST, 03/04/2024 (MT Newswires) -- Earnings Flash (STXS) STEREOTAXIS Reports Q4 Revenue $4.6M, vs. Street Est of $7.7M

MT NewswiresMar 5 05:05

Press Release: Stereotaxis Reports 2023 Full Year Financial Results

Stereotaxis Reports 2023 Full Year Financial Results ST. LOUIS, March 04, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive en

Dow JonesMar 5 05:05